Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02941900 · ClinicalTrials.gov registry record
Interest and Impact of Skin Cancer Genetic Testing
A clinical trial of Non-melanoma Skin Cancer (NMSC), sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 53
- Enrollment target
- 1
- Study location
NCT02941900: Completed study of Non-melanoma Skin Cancer (NMSC), sponsored by Memorial Sloan Kettering Cancer Center.
NCT02941900 is a study of Non-melanoma Skin Cancer (NMSC) that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 53 participants, below the 184-participant average among 3 other Non-melanoma Skin Cancer (NMSC) trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02941900, a study of Non-melanoma Skin Cancer (NMSC), has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn whether the patient might be interested in skin cancer genetic testing, and if so, what kinds of thoughts, feelings, and behaviors might result from this testing. Testing for skin cancer risk based on the MC1R gene is not currently used in clinical practice; it will be offered in this study for research purposes only.
Conditions Studied
Interventions
- BEHAVIORAL Baseline Survey
- GENETIC MC1R genotyping
- BEHAVIORAL MC1R Testing Website
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-08 |
| Est. Completion | 2023-01-18 |
What the finished NCT02941900 record still lists
NCT02941900 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 184-participant average among 3 other Non-melanoma Skin Cancer (NMSC) trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Non-melanoma Skin Cancer (NMSC) appearing as the primary indexed condition, and to 3 interventions - of which Baseline Survey is the first listed.
NCT02941900 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02941900 about?
NCT02941900 is a clinical study titled "Interest and Impact of Skin Cancer Genetic Testing". The purpose of this study is to learn whether the patient might be interested in skin cancer genetic testing, and if so, what kinds of thoughts, feelings, and behaviors might result from this testing. Testing for skin cancer risk based on the MC1R gene is not currently used in clinical practice; it ...
What is the current status of trial NCT02941900?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2016-08. Estimated completion is 2023-01-18.
What conditions does trial NCT02941900 study?
This clinical trial studies the following conditions: Non-melanoma Skin Cancer (NMSC).
What interventions are being tested in trial NCT02941900?
The interventions under investigation include: Baseline Survey (BEHAVIORAL), MC1R genotyping (GENETIC), MC1R Testing Website (BEHAVIORAL).
Who is sponsoring clinical trial NCT02941900?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02941900 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-melanoma Skin Cancer (NMSC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically
RECRUITING
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia